Rachel S. Mulligan

Austin Health — Australia

Medicine · Health Sciences

40h-index6.9kcitations145works1.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(53), Dementia and Cognitive Impairment Research(35), Medical Imaging Techniques and Applications(32), Neuroscience and Neuropharmacology Research(19), Schizophrenia research and treatment(18)

Publications142 total

Reactive Astrogliosis predicts Amyloid Accumulation before the Preclinical Stage of Alzheimer's Disease
Alzheimer s & Dementia·2025Open Access
CenTauR correlation with amyloid, atrophy and cognition across the Alzheimer’s Disease spectrum: A tau imaging study with <sup>18</sup> F‐MK6240 PET
Alzheimer s & Dementia·2025Open Access
Reactive Astrogliosis predicts Amyloid Accumulation before the Preclinical Stage of Alzheimer's Disease
Alzheimer s & Dementia·2025Open Access
CenTauR correlation with amyloid, atrophy and cognition across the Alzheimer's Disease spectrum: A tau imaging study with <sup>18</sup> F‐MK6240 PET
Alzheimer s & Dementia·2025Open Access
Brain 11β-Hydroxysteroid Dehydrogenase Type 1 Occupancy by Xanamem™ Assessed by PET in Alzheimer’s Disease and Cognitively Normal Individuals
Journal of Alzheimer s Disease·2024· 7 citedOpen Access
Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer’s Disease
Journal of Alzheimer s Disease·2023· 30 citedOpen Access
Cross‐sectional and longitudinal comparison of 18F‐MK6240 and 18F‐Flortaucipir in populations matched for centiloid, age and MMSE
Alzheimer s & Dementia·2022
Plasma glial fibrillary acidic protein is associated with reactive astrogliosis assessed via <sup>18</sup>F‐SMBT‐1 PET
Alzheimer s & Dementia·2022
Tau Imaging with <sup>18</sup> F-MK6240 across the Alzheimer’s Disease spectrum
2022· 9 citedOpen Access
Assessing Reactive Astrogliosis with <sup>18</sup>F-SMBT-1 Across the Alzheimer Disease Spectrum
Journal of Nuclear Medicine·2022· 57 citedOpen Access
First-in-Humans Evaluation of <sup>18</sup>F-SMBT-1, a Novel <sup>18</sup>F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis
Journal of Nuclear Medicine·2022· 61 citedOpen Access
<sup>18</sup>F‐MK6240 longitudinal tau PET in ageing and Alzheimer’s disease
Alzheimer s & Dementia·2021· 1 cited
PET Imaging of brain muscarinic receptors with 18F-Fluorobenzyl-Dexetimide: A first in human study
Psychiatry Research Neuroimaging·2021· 10 cited
18F-MK6240 longitudinal tau PET in ageing and Alzheimer's disease
2021· 2 cited
Case Report: 18F-MK6240 Tau Positron Emission Tomography Pattern Resembling Chronic Traumatic Encephalopathy in a Retired Australian Rules Football Player
Frontiers in Neurology·2020· 20 citedOpen Access
Evaluation of the novel <sup>18</sup>F‐labeled PET tracer SMBT‐1 for imaging astrogliosis in healthy elderly controls and A+/T+/(N+) Alzheimer's disease patients
Alzheimer s & Dementia·2020· 4 citedOpen Access
One year tau progression measured with F‐18 MK6240 PET
Alzheimer s & Dementia·2020Open Access
Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals
Neurology·2020· 74 citedOpen Access
Evaluation of the novel F-18-labeled PET tracer SMBT-1 for imaging astrogliosis in Alzheimer's disease
2020
O4‐04‐06: AMYLOID PET IS MORE THAN JUST POSITIVE OR NEGATIVE: AMYLOID LEVEL IMPACTS RISK OF CLINICAL PROGRESSION IN NORMAL INDIVIDUALS
Alzheimer s & Dementia·2019
page 1 of 8Next →

Frequent Co-authors

Victor L. Villemagne(27), Christopher C. Rowe(25), Colin L. Masters(18), Lyn S. Pilowsky(15), Peter J. Ell(15), Gareth Jones(12), Graeme O’Keefe(11), Nobuyuki Okamura(11), Shozo Furumoto(9), Kazuhiko Yanai(9), Svetlana Pejoska(8), Yukitsuka Kudo(8), Henri Tochon‐Danguy(7), Michelle T. Fodero‐Tavoletti(7), Ryuichi Harada(7), Robert Kerwin(7), Vincent Doré(7), Rodrigo A. Bressan(7), Pierrick Bourgeat(6), Kjell Erlandsson(6)